SNIPR001

AXP000216.1 · Phage therapy

Platform
CRISPR-armed phage cocktail (four phages)
Originator
SNIPR Biome
Sponsor
SNIPR Biome

Names

NameTypeSource
SNIPR001preferred name, codecurator, ctgov

Virus

Role
Phage
Family
Caudoviricetes
Virus
Escherichia coli bacteriophage (four-phage cocktail)
Replication
replicating
Modifications
phages armed with a CRISPR-Cas system directed at E. coli
Transgenes
CRISPR-Cas
Route
oral
Source
evidence

Approvals

No regulatory approval recorded.

Clinical trials (2)

TrialTitleStatusPhaseStartPrimary completionEnrolmentConditions
NCT06938867Phase 1b/2a Randomized Double-blind Study to Investigate Safety Tolerability PK PD Preliminary Efficacy of Oral Administration of SNIPR001 in Patients With Hematologic Malignancy Scheduled for Allogeneic Hematopoietic Stem-Cell Transplant Receiving FQ Prophylaxis & Harboring FQR Ecoli Pre-TransplantRecruitingPhase 1/22024-12-042027-1066Allogenic Transplant Patients; E Coli Infections
NCT05277350A Study Investigating the Safety, Recovery, and Pharmacodynamics of Multiple Oral Administrations of SNIPR001 in Healthy SubjectsCompletedPhase 12022-03-242022-11-3036Bloodstream Infection; E.Coli Infections

Recent changes

No changes recorded in its trials yet.

Clinical papers

PubMedTitleJournalYearLinked by
PMID 41785880Safety, recovery, and pharmacodynamics of CRISPR-Cas therapeutic SNIPR001: a phase 1, randomised, double-blind, first-in-human, dose-escalation study.The Lancet. Microbe2026cited by trial NCT05277350

Other papers

Preclinical studies, reviews and other papers that name it.

PubMedTitleJournalYearLinked by
PMID 42262436CRISPR-based gene editing for antimicrobial resistance control in human medicine.Archives of microbiology2026name in abstract: SNIPR001
PMID 42578807First-in-Human Adjunctive Bacteriophage Therapy for Malakoplakia.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America2026name in abstract: SNIPR001
PMID 43010175Engineered bacteriophages as precision antimicrobials against multidrug-resistant ESKAPE pathogens: molecular engineering strategies, clinical translation, and the crystallizing global regulatory landscape.Future science OA2026name in abstract: SNIPR001
PMID 40733529Armed Phages: A New Weapon in the Battle Against Antimicrobial Resistance.Viruses2025name in abstract: SNIPR001
PMID 37142704Engineered phage with antibacterial CRISPR-Cas selectively reduce E. coli burden in mice.Nature biotechnology2024name in abstract: SNIPR001

Notes

Four E. coli phages armed with a CRISPR-Cas payload, given orally to reduce gut E. coli in haematological cancer patients at risk of bloodstream infection. Phase 1 NCT05277350 in healthy volunteers; phase 1b/2a NCT06938867 in patients before allogeneic HSCT.

How to cite

SNIPR001 (AXP000216.1). The Abstractinator program registry, release 2026-11-17+2c46e992acfc. https://abstractinator.me/registry/AXP000216.html

Something wrong or missing? Suggest a correction (a GitHub issue; please link your evidence). Entry created 2026-11-11, updated 2026-11-11.